nodes	percent_of_prediction	percent_of_DWPC	metapath
Zoledronate—ABCC1—Epirubicin—ovarian cancer	0.16	0.31	CbGbCtD
Zoledronate—ABCC1—Paclitaxel—ovarian cancer	0.158	0.305	CbGbCtD
Zoledronate—ABCC1—Docetaxel—ovarian cancer	0.114	0.221	CbGbCtD
Zoledronate—ABCC1—Doxorubicin—ovarian cancer	0.085	0.165	CbGbCtD
Zoledronate—GGPS1—myometrium—ovarian cancer	0.00922	0.0708	CbGeAlD
Zoledronate—GGPS1—uterine cervix—ovarian cancer	0.00718	0.0551	CbGeAlD
Zoledronate—GGPS1—decidua—ovarian cancer	0.00684	0.0525	CbGeAlD
Zoledronate—GGPS1—endometrium—ovarian cancer	0.00649	0.0498	CbGeAlD
Zoledronate—GGPS1—gonad—ovarian cancer	0.00602	0.0462	CbGeAlD
Zoledronate—GGPS1—uterus—ovarian cancer	0.00598	0.0459	CbGeAlD
Zoledronate—GGPS1—female reproductive system—ovarian cancer	0.00538	0.0413	CbGeAlD
Zoledronate—GGPS1—bone marrow—ovarian cancer	0.00508	0.039	CbGeAlD
Zoledronate—GGPS1—female gonad—ovarian cancer	0.00489	0.0376	CbGeAlD
Zoledronate—GGPS1—vagina—ovarian cancer	0.00486	0.0373	CbGeAlD
Zoledronate—GGPS1—testis—ovarian cancer	0.00434	0.0333	CbGeAlD
Zoledronate—FDPS—myometrium—ovarian cancer	0.00425	0.0326	CbGeAlD
Zoledronate—FDPS—uterine cervix—ovarian cancer	0.00331	0.0254	CbGeAlD
Zoledronate—FDPS—decidua—ovarian cancer	0.00315	0.0242	CbGeAlD
Zoledronate—GGPS1—lymph node—ovarian cancer	0.00315	0.0242	CbGeAlD
Zoledronate—FDPS—endometrium—ovarian cancer	0.00299	0.023	CbGeAlD
Zoledronate—FDPS—gonad—ovarian cancer	0.00278	0.0213	CbGeAlD
Zoledronate—FDPS—uterus—ovarian cancer	0.00276	0.0212	CbGeAlD
Zoledronate—CA12—female reproductive system—ovarian cancer	0.00251	0.0192	CbGeAlD
Zoledronate—FDPS—female reproductive system—ovarian cancer	0.00248	0.019	CbGeAlD
Zoledronate—ABCC1—myometrium—ovarian cancer	0.00247	0.019	CbGeAlD
Zoledronate—FDPS—bone marrow—ovarian cancer	0.00234	0.018	CbGeAlD
Zoledronate—FDPS—female gonad—ovarian cancer	0.00226	0.0173	CbGeAlD
Zoledronate—FDPS—vagina—ovarian cancer	0.00224	0.0172	CbGeAlD
Zoledronate—CA2—embryo—ovarian cancer	0.00212	0.0163	CbGeAlD
Zoledronate—FDPS—testis—ovarian cancer	0.002	0.0154	CbGeAlD
Zoledronate—ABCC1—uterine cervix—ovarian cancer	0.00192	0.0148	CbGeAlD
Zoledronate—ABCC1—decidua—ovarian cancer	0.00183	0.0141	CbGeAlD
Zoledronate—ABCC1—endometrium—ovarian cancer	0.00174	0.0133	CbGeAlD
Zoledronate—CA2—epithelium—ovarian cancer	0.00173	0.0133	CbGeAlD
Zoledronate—CA2—decidua—ovarian cancer	0.00164	0.0126	CbGeAlD
Zoledronate—ABCC1—uterus—ovarian cancer	0.0016	0.0123	CbGeAlD
Zoledronate—FDPS—lymph node—ovarian cancer	0.00145	0.0111	CbGeAlD
Zoledronate—ABCC1—female gonad—ovarian cancer	0.00131	0.0101	CbGeAlD
Zoledronate—ABCC1—vagina—ovarian cancer	0.0013	0.01	CbGeAlD
Zoledronate—CA2—female reproductive system—ovarian cancer	0.00129	0.00988	CbGeAlD
Zoledronate—CA2—bone marrow—ovarian cancer	0.00122	0.00933	CbGeAlD
Zoledronate—CA2—female gonad—ovarian cancer	0.00117	0.00899	CbGeAlD
Zoledronate—CA2—vagina—ovarian cancer	0.00116	0.00894	CbGeAlD
Zoledronate—ABCC1—testis—ovarian cancer	0.00116	0.00892	CbGeAlD
Zoledronate—GGPS1—Activation of gene expression by SREBF (SREBP)—FASN—ovarian cancer	0.00105	0.116	CbGpPWpGaD
Zoledronate—CA2—testis—ovarian cancer	0.00104	0.00797	CbGeAlD
Zoledronate—ABCC1—lymph node—ovarian cancer	0.000842	0.00647	CbGeAlD
Zoledronate—GGPS1—Regulation of cholesterol biosynthesis by SREBP (SREBF)—FASN—ovarian cancer	0.000841	0.0926	CbGpPWpGaD
Zoledronate—CA2—lymph node—ovarian cancer	0.000753	0.00578	CbGeAlD
Zoledronate—FDPS—Activation of gene expression by SREBF (SREBP)—FASN—ovarian cancer	0.000449	0.0495	CbGpPWpGaD
Zoledronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—FASN—ovarian cancer	0.000359	0.0395	CbGpPWpGaD
Zoledronate—FDPS—SREBP signalling—FASN—ovarian cancer	0.000291	0.032	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.00023	0.0254	CbGpPWpGaD
Zoledronate—ABCC1—Irinotecan Pathway—APC—ovarian cancer	0.000201	0.0221	CbGpPWpGaD
Zoledronate—Cough—Docetaxel—ovarian cancer	0.000196	0.00057	CcSEcCtD
Zoledronate—Insomnia—Paclitaxel—ovarian cancer	0.000195	0.000568	CcSEcCtD
Zoledronate—Convulsion—Docetaxel—ovarian cancer	0.000194	0.000566	CcSEcCtD
Zoledronate—Paraesthesia—Paclitaxel—ovarian cancer	0.000194	0.000564	CcSEcCtD
Zoledronate—Hypertension—Docetaxel—ovarian cancer	0.000194	0.000564	CcSEcCtD
Zoledronate—Infestation NOS—Epirubicin—ovarian cancer	0.000194	0.000563	CcSEcCtD
Zoledronate—Infestation—Epirubicin—ovarian cancer	0.000194	0.000563	CcSEcCtD
Zoledronate—Dyspnoea—Paclitaxel—ovarian cancer	0.000193	0.00056	CcSEcCtD
Zoledronate—Somnolence—Paclitaxel—ovarian cancer	0.000192	0.000559	CcSEcCtD
Zoledronate—Arthralgia—Docetaxel—ovarian cancer	0.000191	0.000556	CcSEcCtD
Zoledronate—Myalgia—Docetaxel—ovarian cancer	0.000191	0.000556	CcSEcCtD
Zoledronate—Chest pain—Docetaxel—ovarian cancer	0.000191	0.000556	CcSEcCtD
Zoledronate—Pancytopenia—Doxorubicin—ovarian cancer	0.000191	0.000555	CcSEcCtD
Zoledronate—Nausea—Vinorelbine—ovarian cancer	0.000191	0.000555	CcSEcCtD
Zoledronate—Renal failure—Epirubicin—ovarian cancer	0.00019	0.000554	CcSEcCtD
Zoledronate—Dyspepsia—Paclitaxel—ovarian cancer	0.00019	0.000553	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00019	0.000552	CcSEcCtD
Zoledronate—Stomatitis—Epirubicin—ovarian cancer	0.000189	0.000549	CcSEcCtD
Zoledronate—Conjunctivitis—Epirubicin—ovarian cancer	0.000188	0.000548	CcSEcCtD
Zoledronate—Urinary tract infection—Epirubicin—ovarian cancer	0.000188	0.000548	CcSEcCtD
Zoledronate—Neutropenia—Doxorubicin—ovarian cancer	0.000188	0.000547	CcSEcCtD
Zoledronate—Decreased appetite—Paclitaxel—ovarian cancer	0.000188	0.000546	CcSEcCtD
Zoledronate—Dry mouth—Docetaxel—ovarian cancer	0.000187	0.000543	CcSEcCtD
Zoledronate—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000187	0.000543	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000187	0.000543	CcSEcCtD
Zoledronate—Fatigue—Paclitaxel—ovarian cancer	0.000186	0.000542	CcSEcCtD
Zoledronate—Pollakiuria—Doxorubicin—ovarian cancer	0.000186	0.00054	CcSEcCtD
Zoledronate—Constipation—Paclitaxel—ovarian cancer	0.000185	0.000537	CcSEcCtD
Zoledronate—Pain—Paclitaxel—ovarian cancer	0.000185	0.000537	CcSEcCtD
Zoledronate—Haematuria—Epirubicin—ovarian cancer	0.000185	0.000537	CcSEcCtD
Zoledronate—Confusional state—Docetaxel—ovarian cancer	0.000185	0.000537	CcSEcCtD
Zoledronate—Anaphylactic shock—Docetaxel—ovarian cancer	0.000183	0.000533	CcSEcCtD
Zoledronate—Oedema—Docetaxel—ovarian cancer	0.000183	0.000533	CcSEcCtD
Zoledronate—Weight increased—Doxorubicin—ovarian cancer	0.000183	0.000532	CcSEcCtD
Zoledronate—GGPS1—Metabolism—NME2—ovarian cancer	0.000182	0.0201	CbGpPWpGaD
Zoledronate—Infection—Docetaxel—ovarian cancer	0.000182	0.000529	CcSEcCtD
Zoledronate—Weight decreased—Doxorubicin—ovarian cancer	0.000182	0.000529	CcSEcCtD
Zoledronate—Agranulocytosis—Epirubicin—ovarian cancer	0.000181	0.000526	CcSEcCtD
Zoledronate—Shock—Docetaxel—ovarian cancer	0.00018	0.000524	CcSEcCtD
Zoledronate—Nervous system disorder—Docetaxel—ovarian cancer	0.00018	0.000522	CcSEcCtD
Zoledronate—Thrombocytopenia—Docetaxel—ovarian cancer	0.000179	0.000522	CcSEcCtD
Zoledronate—Infestation—Doxorubicin—ovarian cancer	0.000179	0.000521	CcSEcCtD
Zoledronate—Infestation NOS—Doxorubicin—ovarian cancer	0.000179	0.000521	CcSEcCtD
Zoledronate—Tachycardia—Docetaxel—ovarian cancer	0.000179	0.00052	CcSEcCtD
Zoledronate—Feeling abnormal—Paclitaxel—ovarian cancer	0.000178	0.000518	CcSEcCtD
Zoledronate—Skin disorder—Docetaxel—ovarian cancer	0.000178	0.000517	CcSEcCtD
Zoledronate—Bradycardia—Epirubicin—ovarian cancer	0.000177	0.000515	CcSEcCtD
Zoledronate—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000177	0.000514	CcSEcCtD
Zoledronate—Renal failure—Doxorubicin—ovarian cancer	0.000176	0.000512	CcSEcCtD
Zoledronate—Stomatitis—Doxorubicin—ovarian cancer	0.000175	0.000508	CcSEcCtD
Zoledronate—Anorexia—Docetaxel—ovarian cancer	0.000175	0.000508	CcSEcCtD
Zoledronate—Conjunctivitis—Doxorubicin—ovarian cancer	0.000174	0.000507	CcSEcCtD
Zoledronate—Urinary tract infection—Doxorubicin—ovarian cancer	0.000174	0.000507	CcSEcCtD
Zoledronate—Hypoaesthesia—Epirubicin—ovarian cancer	0.000173	0.000503	CcSEcCtD
Zoledronate—Urinary tract disorder—Epirubicin—ovarian cancer	0.000172	0.000499	CcSEcCtD
Zoledronate—Urticaria—Paclitaxel—ovarian cancer	0.000172	0.000499	CcSEcCtD
Zoledronate—Oedema peripheral—Epirubicin—ovarian cancer	0.000171	0.000498	CcSEcCtD
Zoledronate—Hypotension—Docetaxel—ovarian cancer	0.000171	0.000498	CcSEcCtD
Zoledronate—Haematuria—Doxorubicin—ovarian cancer	0.000171	0.000497	CcSEcCtD
Zoledronate—Connective tissue disorder—Epirubicin—ovarian cancer	0.000171	0.000497	CcSEcCtD
Zoledronate—Body temperature increased—Paclitaxel—ovarian cancer	0.000171	0.000497	CcSEcCtD
Zoledronate—Abdominal pain—Paclitaxel—ovarian cancer	0.000171	0.000497	CcSEcCtD
Zoledronate—Urethral disorder—Epirubicin—ovarian cancer	0.00017	0.000496	CcSEcCtD
Zoledronate—Agranulocytosis—Doxorubicin—ovarian cancer	0.000167	0.000486	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000167	0.000485	CcSEcCtD
Zoledronate—Insomnia—Docetaxel—ovarian cancer	0.000166	0.000482	CcSEcCtD
Zoledronate—Paraesthesia—Docetaxel—ovarian cancer	0.000164	0.000478	CcSEcCtD
Zoledronate—Bradycardia—Doxorubicin—ovarian cancer	0.000164	0.000476	CcSEcCtD
Zoledronate—Dyspnoea—Docetaxel—ovarian cancer	0.000163	0.000475	CcSEcCtD
Zoledronate—Somnolence—Docetaxel—ovarian cancer	0.000163	0.000474	CcSEcCtD
Zoledronate—Eye disorder—Epirubicin—ovarian cancer	0.000162	0.000473	CcSEcCtD
Zoledronate—Flushing—Epirubicin—ovarian cancer	0.000161	0.000469	CcSEcCtD
Zoledronate—Cardiac disorder—Epirubicin—ovarian cancer	0.000161	0.000469	CcSEcCtD
Zoledronate—Dyspepsia—Docetaxel—ovarian cancer	0.000161	0.000469	CcSEcCtD
Zoledronate—Hypoaesthesia—Doxorubicin—ovarian cancer	0.00016	0.000466	CcSEcCtD
Zoledronate—Decreased appetite—Docetaxel—ovarian cancer	0.000159	0.000463	CcSEcCtD
Zoledronate—Hypersensitivity—Paclitaxel—ovarian cancer	0.000159	0.000463	CcSEcCtD
Zoledronate—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000159	0.000462	CcSEcCtD
Zoledronate—Oedema peripheral—Doxorubicin—ovarian cancer	0.000158	0.000461	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000158	0.00046	CcSEcCtD
Zoledronate—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000158	0.00046	CcSEcCtD
Zoledronate—Fatigue—Docetaxel—ovarian cancer	0.000158	0.000459	CcSEcCtD
Zoledronate—Angiopathy—Epirubicin—ovarian cancer	0.000158	0.000459	CcSEcCtD
Zoledronate—Urethral disorder—Doxorubicin—ovarian cancer	0.000158	0.000459	CcSEcCtD
Zoledronate—Immune system disorder—Epirubicin—ovarian cancer	0.000157	0.000457	CcSEcCtD
Zoledronate—Mediastinal disorder—Epirubicin—ovarian cancer	0.000157	0.000456	CcSEcCtD
Zoledronate—Pain—Docetaxel—ovarian cancer	0.000157	0.000456	CcSEcCtD
Zoledronate—Constipation—Docetaxel—ovarian cancer	0.000157	0.000456	CcSEcCtD
Zoledronate—Chills—Epirubicin—ovarian cancer	0.000156	0.000454	CcSEcCtD
Zoledronate—Arrhythmia—Epirubicin—ovarian cancer	0.000155	0.000452	CcSEcCtD
Zoledronate—Asthenia—Paclitaxel—ovarian cancer	0.000155	0.000451	CcSEcCtD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000154	0.017	CbGpPWpGaD
Zoledronate—Alopecia—Epirubicin—ovarian cancer	0.000154	0.000447	CcSEcCtD
Zoledronate—Pruritus—Paclitaxel—ovarian cancer	0.000153	0.000445	CcSEcCtD
Zoledronate—Mental disorder—Epirubicin—ovarian cancer	0.000152	0.000443	CcSEcCtD
Zoledronate—Erythema—Epirubicin—ovarian cancer	0.000151	0.00044	CcSEcCtD
Zoledronate—Malnutrition—Epirubicin—ovarian cancer	0.000151	0.00044	CcSEcCtD
Zoledronate—Feeling abnormal—Docetaxel—ovarian cancer	0.000151	0.000439	CcSEcCtD
Zoledronate—Eye disorder—Doxorubicin—ovarian cancer	0.00015	0.000437	CcSEcCtD
Zoledronate—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00015	0.000436	CcSEcCtD
Zoledronate—Cardiac disorder—Doxorubicin—ovarian cancer	0.000149	0.000434	CcSEcCtD
Zoledronate—Flushing—Doxorubicin—ovarian cancer	0.000149	0.000434	CcSEcCtD
Zoledronate—Dysgeusia—Epirubicin—ovarian cancer	0.000148	0.000431	CcSEcCtD
Zoledronate—Diarrhoea—Paclitaxel—ovarian cancer	0.000148	0.00043	CcSEcCtD
Zoledronate—Back pain—Epirubicin—ovarian cancer	0.000146	0.000426	CcSEcCtD
Zoledronate—Angiopathy—Doxorubicin—ovarian cancer	0.000146	0.000425	CcSEcCtD
Zoledronate—Muscle spasms—Epirubicin—ovarian cancer	0.000146	0.000423	CcSEcCtD
Zoledronate—Immune system disorder—Doxorubicin—ovarian cancer	0.000145	0.000423	CcSEcCtD
Zoledronate—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000145	0.000422	CcSEcCtD
Zoledronate—Abdominal pain—Docetaxel—ovarian cancer	0.000145	0.000421	CcSEcCtD
Zoledronate—Body temperature increased—Docetaxel—ovarian cancer	0.000145	0.000421	CcSEcCtD
Zoledronate—Chills—Doxorubicin—ovarian cancer	0.000144	0.00042	CcSEcCtD
Zoledronate—Arrhythmia—Doxorubicin—ovarian cancer	0.000144	0.000418	CcSEcCtD
Zoledronate—Dizziness—Paclitaxel—ovarian cancer	0.000143	0.000416	CcSEcCtD
Zoledronate—Vision blurred—Epirubicin—ovarian cancer	0.000143	0.000415	CcSEcCtD
Zoledronate—Alopecia—Doxorubicin—ovarian cancer	0.000142	0.000413	CcSEcCtD
Zoledronate—Mental disorder—Doxorubicin—ovarian cancer	0.000141	0.00041	CcSEcCtD
Zoledronate—Ill-defined disorder—Epirubicin—ovarian cancer	0.00014	0.000408	CcSEcCtD
Zoledronate—Malnutrition—Doxorubicin—ovarian cancer	0.00014	0.000407	CcSEcCtD
Zoledronate—Erythema—Doxorubicin—ovarian cancer	0.00014	0.000407	CcSEcCtD
Zoledronate—Anaemia—Epirubicin—ovarian cancer	0.00014	0.000407	CcSEcCtD
Zoledronate—Agitation—Epirubicin—ovarian cancer	0.000139	0.000405	CcSEcCtD
Zoledronate—Vomiting—Paclitaxel—ovarian cancer	0.000137	0.0004	CcSEcCtD
Zoledronate—Dysgeusia—Doxorubicin—ovarian cancer	0.000137	0.000399	CcSEcCtD
Zoledronate—Malaise—Epirubicin—ovarian cancer	0.000136	0.000397	CcSEcCtD
Zoledronate—Rash—Paclitaxel—ovarian cancer	0.000136	0.000396	CcSEcCtD
Zoledronate—Dermatitis—Paclitaxel—ovarian cancer	0.000136	0.000396	CcSEcCtD
Zoledronate—Vertigo—Epirubicin—ovarian cancer	0.000136	0.000396	CcSEcCtD
Zoledronate—Syncope—Epirubicin—ovarian cancer	0.000136	0.000395	CcSEcCtD
Zoledronate—Leukopenia—Epirubicin—ovarian cancer	0.000135	0.000394	CcSEcCtD
Zoledronate—Back pain—Doxorubicin—ovarian cancer	0.000135	0.000394	CcSEcCtD
Zoledronate—Headache—Paclitaxel—ovarian cancer	0.000135	0.000394	CcSEcCtD
Zoledronate—Hypersensitivity—Docetaxel—ovarian cancer	0.000135	0.000392	CcSEcCtD
Zoledronate—Muscle spasms—Doxorubicin—ovarian cancer	0.000135	0.000392	CcSEcCtD
Zoledronate—Palpitations—Epirubicin—ovarian cancer	0.000134	0.000389	CcSEcCtD
Zoledronate—Loss of consciousness—Epirubicin—ovarian cancer	0.000133	0.000387	CcSEcCtD
Zoledronate—Cough—Epirubicin—ovarian cancer	0.000132	0.000384	CcSEcCtD
Zoledronate—Vision blurred—Doxorubicin—ovarian cancer	0.000132	0.000384	CcSEcCtD
Zoledronate—Asthenia—Docetaxel—ovarian cancer	0.000131	0.000382	CcSEcCtD
Zoledronate—Convulsion—Epirubicin—ovarian cancer	0.000131	0.000381	CcSEcCtD
Zoledronate—ABCC1—ABC-family proteins mediated transport—ABCB1—ovarian cancer	0.000131	0.0144	CbGpPWpGaD
Zoledronate—Hypertension—Epirubicin—ovarian cancer	0.000131	0.00038	CcSEcCtD
Zoledronate—Ill-defined disorder—Doxorubicin—ovarian cancer	0.00013	0.000378	CcSEcCtD
Zoledronate—Pruritus—Docetaxel—ovarian cancer	0.00013	0.000377	CcSEcCtD
Zoledronate—Anaemia—Doxorubicin—ovarian cancer	0.000129	0.000376	CcSEcCtD
Zoledronate—Arthralgia—Epirubicin—ovarian cancer	0.000129	0.000375	CcSEcCtD
Zoledronate—Myalgia—Epirubicin—ovarian cancer	0.000129	0.000375	CcSEcCtD
Zoledronate—Chest pain—Epirubicin—ovarian cancer	0.000129	0.000375	CcSEcCtD
Zoledronate—Agitation—Doxorubicin—ovarian cancer	0.000129	0.000374	CcSEcCtD
Zoledronate—Anxiety—Epirubicin—ovarian cancer	0.000128	0.000374	CcSEcCtD
Zoledronate—Nausea—Paclitaxel—ovarian cancer	0.000128	0.000373	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000128	0.000372	CcSEcCtD
Zoledronate—Discomfort—Epirubicin—ovarian cancer	0.000127	0.00037	CcSEcCtD
Zoledronate—Malaise—Doxorubicin—ovarian cancer	0.000126	0.000367	CcSEcCtD
Zoledronate—Dry mouth—Epirubicin—ovarian cancer	0.000126	0.000367	CcSEcCtD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000126	0.0139	CbGpPWpGaD
Zoledronate—Vertigo—Doxorubicin—ovarian cancer	0.000126	0.000366	CcSEcCtD
Zoledronate—Syncope—Doxorubicin—ovarian cancer	0.000126	0.000365	CcSEcCtD
Zoledronate—Leukopenia—Doxorubicin—ovarian cancer	0.000125	0.000365	CcSEcCtD
Zoledronate—Diarrhoea—Docetaxel—ovarian cancer	0.000125	0.000364	CcSEcCtD
Zoledronate—Confusional state—Epirubicin—ovarian cancer	0.000125	0.000362	CcSEcCtD
Zoledronate—Palpitations—Doxorubicin—ovarian cancer	0.000124	0.00036	CcSEcCtD
Zoledronate—Oedema—Epirubicin—ovarian cancer	0.000124	0.000359	CcSEcCtD
Zoledronate—Anaphylactic shock—Epirubicin—ovarian cancer	0.000124	0.000359	CcSEcCtD
Zoledronate—Loss of consciousness—Doxorubicin—ovarian cancer	0.000123	0.000358	CcSEcCtD
Zoledronate—Infection—Epirubicin—ovarian cancer	0.000123	0.000357	CcSEcCtD
Zoledronate—Cough—Doxorubicin—ovarian cancer	0.000122	0.000355	CcSEcCtD
Zoledronate—ABCC1—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000122	0.0135	CbGpPWpGaD
Zoledronate—Shock—Epirubicin—ovarian cancer	0.000122	0.000353	CcSEcCtD
Zoledronate—Convulsion—Doxorubicin—ovarian cancer	0.000121	0.000353	CcSEcCtD
Zoledronate—Nervous system disorder—Epirubicin—ovarian cancer	0.000121	0.000352	CcSEcCtD
Zoledronate—Dizziness—Docetaxel—ovarian cancer	0.000121	0.000352	CcSEcCtD
Zoledronate—Thrombocytopenia—Epirubicin—ovarian cancer	0.000121	0.000352	CcSEcCtD
Zoledronate—Hypertension—Doxorubicin—ovarian cancer	0.000121	0.000352	CcSEcCtD
Zoledronate—Tachycardia—Epirubicin—ovarian cancer	0.000121	0.000351	CcSEcCtD
Zoledronate—FDPS—SREBP signalling—MTOR—ovarian cancer	0.00012	0.0133	CbGpPWpGaD
Zoledronate—Skin disorder—Epirubicin—ovarian cancer	0.00012	0.000349	CcSEcCtD
Zoledronate—Hyperhidrosis—Epirubicin—ovarian cancer	0.000119	0.000347	CcSEcCtD
Zoledronate—Myalgia—Doxorubicin—ovarian cancer	0.000119	0.000347	CcSEcCtD
Zoledronate—Arthralgia—Doxorubicin—ovarian cancer	0.000119	0.000347	CcSEcCtD
Zoledronate—Chest pain—Doxorubicin—ovarian cancer	0.000119	0.000347	CcSEcCtD
Zoledronate—Anxiety—Doxorubicin—ovarian cancer	0.000119	0.000346	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000118	0.000344	CcSEcCtD
Zoledronate—Discomfort—Doxorubicin—ovarian cancer	0.000118	0.000343	CcSEcCtD
Zoledronate—Anorexia—Epirubicin—ovarian cancer	0.000118	0.000342	CcSEcCtD
Zoledronate—GGPS1—Metabolism—CYTB—ovarian cancer	0.000117	0.0129	CbGpPWpGaD
Zoledronate—Dry mouth—Doxorubicin—ovarian cancer	0.000117	0.000339	CcSEcCtD
Zoledronate—Vomiting—Docetaxel—ovarian cancer	0.000116	0.000339	CcSEcCtD
Zoledronate—Rash—Docetaxel—ovarian cancer	0.000115	0.000336	CcSEcCtD
Zoledronate—Hypotension—Epirubicin—ovarian cancer	0.000115	0.000336	CcSEcCtD
Zoledronate—Dermatitis—Docetaxel—ovarian cancer	0.000115	0.000336	CcSEcCtD
Zoledronate—Confusional state—Doxorubicin—ovarian cancer	0.000115	0.000335	CcSEcCtD
Zoledronate—Headache—Docetaxel—ovarian cancer	0.000115	0.000334	CcSEcCtD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000115	0.0126	CbGpPWpGaD
Zoledronate—Oedema—Doxorubicin—ovarian cancer	0.000114	0.000332	CcSEcCtD
Zoledronate—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000114	0.000332	CcSEcCtD
Zoledronate—Infection—Doxorubicin—ovarian cancer	0.000114	0.00033	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000113	0.000327	CcSEcCtD
Zoledronate—Shock—Doxorubicin—ovarian cancer	0.000112	0.000327	CcSEcCtD
Zoledronate—Nervous system disorder—Doxorubicin—ovarian cancer	0.000112	0.000326	CcSEcCtD
Zoledronate—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000112	0.000326	CcSEcCtD
Zoledronate—Insomnia—Epirubicin—ovarian cancer	0.000112	0.000325	CcSEcCtD
Zoledronate—Tachycardia—Doxorubicin—ovarian cancer	0.000112	0.000324	CcSEcCtD
Zoledronate—Skin disorder—Doxorubicin—ovarian cancer	0.000111	0.000323	CcSEcCtD
Zoledronate—Paraesthesia—Epirubicin—ovarian cancer	0.000111	0.000323	CcSEcCtD
Zoledronate—Hyperhidrosis—Doxorubicin—ovarian cancer	0.00011	0.000321	CcSEcCtD
Zoledronate—Dyspnoea—Epirubicin—ovarian cancer	0.00011	0.00032	CcSEcCtD
Zoledronate—Somnolence—Epirubicin—ovarian cancer	0.00011	0.000319	CcSEcCtD
Zoledronate—Anorexia—Doxorubicin—ovarian cancer	0.000109	0.000317	CcSEcCtD
Zoledronate—Nausea—Docetaxel—ovarian cancer	0.000109	0.000316	CcSEcCtD
Zoledronate—Dyspepsia—Epirubicin—ovarian cancer	0.000109	0.000316	CcSEcCtD
Zoledronate—Decreased appetite—Epirubicin—ovarian cancer	0.000107	0.000312	CcSEcCtD
Zoledronate—Hypotension—Doxorubicin—ovarian cancer	0.000107	0.000311	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000107	0.00031	CcSEcCtD
Zoledronate—Fatigue—Epirubicin—ovarian cancer	0.000107	0.00031	CcSEcCtD
Zoledronate—Pain—Epirubicin—ovarian cancer	0.000106	0.000307	CcSEcCtD
Zoledronate—Constipation—Epirubicin—ovarian cancer	0.000106	0.000307	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000104	0.000303	CcSEcCtD
Zoledronate—Insomnia—Doxorubicin—ovarian cancer	0.000103	0.000301	CcSEcCtD
Zoledronate—Paraesthesia—Doxorubicin—ovarian cancer	0.000103	0.000299	CcSEcCtD
Zoledronate—GGPS1—Metabolism—BRIP1—ovarian cancer	0.000103	0.0113	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PPP1CC—ovarian cancer	0.000103	0.0113	CbGpPWpGaD
Zoledronate—Dyspnoea—Doxorubicin—ovarian cancer	0.000102	0.000296	CcSEcCtD
Zoledronate—Feeling abnormal—Epirubicin—ovarian cancer	0.000102	0.000296	CcSEcCtD
Zoledronate—Somnolence—Doxorubicin—ovarian cancer	0.000102	0.000296	CcSEcCtD
Zoledronate—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000101	0.000294	CcSEcCtD
Zoledronate—Dyspepsia—Doxorubicin—ovarian cancer	0.000101	0.000293	CcSEcCtD
Zoledronate—Decreased appetite—Doxorubicin—ovarian cancer	9.94e-05	0.000289	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Doxorubicin—ovarian cancer	9.87e-05	0.000287	CcSEcCtD
Zoledronate—Fatigue—Doxorubicin—ovarian cancer	9.85e-05	0.000287	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	9.83e-05	0.0108	CbGpPWpGaD
Zoledronate—Urticaria—Epirubicin—ovarian cancer	9.81e-05	0.000285	CcSEcCtD
Zoledronate—Constipation—Doxorubicin—ovarian cancer	9.77e-05	0.000284	CcSEcCtD
Zoledronate—Pain—Doxorubicin—ovarian cancer	9.77e-05	0.000284	CcSEcCtD
Zoledronate—Body temperature increased—Epirubicin—ovarian cancer	9.77e-05	0.000284	CcSEcCtD
Zoledronate—Abdominal pain—Epirubicin—ovarian cancer	9.77e-05	0.000284	CcSEcCtD
Zoledronate—Feeling abnormal—Doxorubicin—ovarian cancer	9.42e-05	0.000274	CcSEcCtD
Zoledronate—ABCC1—S1P1 pathway—VEGFA—ovarian cancer	9.41e-05	0.0104	CbGpPWpGaD
Zoledronate—Gastrointestinal pain—Doxorubicin—ovarian cancer	9.35e-05	0.000272	CcSEcCtD
Zoledronate—Hypersensitivity—Epirubicin—ovarian cancer	9.1e-05	0.000265	CcSEcCtD
Zoledronate—Urticaria—Doxorubicin—ovarian cancer	9.08e-05	0.000264	CcSEcCtD
Zoledronate—Abdominal pain—Doxorubicin—ovarian cancer	9.04e-05	0.000263	CcSEcCtD
Zoledronate—Body temperature increased—Doxorubicin—ovarian cancer	9.04e-05	0.000263	CcSEcCtD
Zoledronate—ABCC1—S1P1 pathway—MAPK3—ovarian cancer	8.9e-05	0.0098	CbGpPWpGaD
Zoledronate—CA14—Metabolism—NME2—ovarian cancer	8.89e-05	0.00979	CbGpPWpGaD
Zoledronate—Asthenia—Epirubicin—ovarian cancer	8.86e-05	0.000258	CcSEcCtD
Zoledronate—Pruritus—Epirubicin—ovarian cancer	8.74e-05	0.000254	CcSEcCtD
Zoledronate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—FASN—ovarian cancer	8.61e-05	0.00949	CbGpPWpGaD
Zoledronate—ABCC1—S1P1 pathway—MAPK1—ovarian cancer	8.47e-05	0.00933	CbGpPWpGaD
Zoledronate—Diarrhoea—Epirubicin—ovarian cancer	8.45e-05	0.000246	CcSEcCtD
Zoledronate—Hypersensitivity—Doxorubicin—ovarian cancer	8.42e-05	0.000245	CcSEcCtD
Zoledronate—Asthenia—Doxorubicin—ovarian cancer	8.2e-05	0.000239	CcSEcCtD
Zoledronate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—ovarian cancer	8.18e-05	0.00901	CbGpPWpGaD
Zoledronate—Dizziness—Epirubicin—ovarian cancer	8.17e-05	0.000238	CcSEcCtD
Zoledronate—Pruritus—Doxorubicin—ovarian cancer	8.09e-05	0.000235	CcSEcCtD
Zoledronate—Vomiting—Epirubicin—ovarian cancer	7.85e-05	0.000228	CcSEcCtD
Zoledronate—Diarrhoea—Doxorubicin—ovarian cancer	7.82e-05	0.000227	CcSEcCtD
Zoledronate—Rash—Epirubicin—ovarian cancer	7.79e-05	0.000227	CcSEcCtD
Zoledronate—Dermatitis—Epirubicin—ovarian cancer	7.78e-05	0.000226	CcSEcCtD
Zoledronate—FDPS—Metabolism—NME2—ovarian cancer	7.77e-05	0.00856	CbGpPWpGaD
Zoledronate—Headache—Epirubicin—ovarian cancer	7.74e-05	0.000225	CcSEcCtD
Zoledronate—Dizziness—Doxorubicin—ovarian cancer	7.56e-05	0.00022	CcSEcCtD
Zoledronate—CA12—Metabolism—NME2—ovarian cancer	7.49e-05	0.00825	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	7.47e-05	0.00823	CbGpPWpGaD
Zoledronate—FDPS—SREBP signalling—PIK3CA—ovarian cancer	7.34e-05	0.00808	CbGpPWpGaD
Zoledronate—Nausea—Epirubicin—ovarian cancer	7.34e-05	0.000213	CcSEcCtD
Zoledronate—Vomiting—Doxorubicin—ovarian cancer	7.27e-05	0.000211	CcSEcCtD
Zoledronate—Rash—Doxorubicin—ovarian cancer	7.21e-05	0.00021	CcSEcCtD
Zoledronate—Dermatitis—Doxorubicin—ovarian cancer	7.2e-05	0.000209	CcSEcCtD
Zoledronate—Headache—Doxorubicin—ovarian cancer	7.16e-05	0.000208	CcSEcCtD
Zoledronate—GGPS1—Metabolism—YAP1—ovarian cancer	6.88e-05	0.00757	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.81e-05	0.0075	CbGpPWpGaD
Zoledronate—Nausea—Doxorubicin—ovarian cancer	6.79e-05	0.000197	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	6.59e-05	0.00726	CbGpPWpGaD
Zoledronate—FDPS—SREBP signalling—AKT1—ovarian cancer	5.99e-05	0.0066	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.98e-05	0.00659	CbGpPWpGaD
Zoledronate—CA2—Metabolism—NME2—ovarian cancer	5.73e-05	0.00631	CbGpPWpGaD
Zoledronate—CA14—Metabolism—CYTB—ovarian cancer	5.73e-05	0.00631	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—FASN—ovarian cancer	5.61e-05	0.00617	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—SLC5A5—ovarian cancer	5.51e-05	0.00607	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.37e-05	0.00592	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—SLC2A1—ovarian cancer	5.33e-05	0.00587	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.21e-05	0.00574	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—CYP1B1—ovarian cancer	5.11e-05	0.00562	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CYTB—ovarian cancer	5.01e-05	0.00552	CbGpPWpGaD
Zoledronate—CA14—Metabolism—BRIP1—ovarian cancer	5.01e-05	0.00552	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PPP1CC—ovarian cancer	5.01e-05	0.00552	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.89e-05	0.00539	CbGpPWpGaD
Zoledronate—CA12—Metabolism—CYTB—ovarian cancer	4.83e-05	0.00532	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PPP2R1A—ovarian cancer	4.53e-05	0.00499	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.51e-05	0.00496	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PPP1CC—ovarian cancer	4.38e-05	0.00482	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—BRIP1—ovarian cancer	4.38e-05	0.00482	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PPP1CC—ovarian cancer	4.22e-05	0.00465	CbGpPWpGaD
Zoledronate—CA12—Metabolism—BRIP1—ovarian cancer	4.22e-05	0.00465	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—ABCB1—ovarian cancer	4.2e-05	0.00463	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—TYMS—ovarian cancer	4.13e-05	0.00455	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CYTB—ovarian cancer	3.69e-05	0.00407	CbGpPWpGaD
Zoledronate—ABCC1—Disease—HSD17B6—ovarian cancer	3.62e-05	0.00399	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—AQP3—ovarian cancer	3.55e-05	0.00391	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	3.51e-05	0.00386	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	3.4e-05	0.00375	CbGpPWpGaD
Zoledronate—CA14—Metabolism—YAP1—ovarian cancer	3.36e-05	0.0037	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—CAV1—ovarian cancer	3.33e-05	0.00367	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PPP1CC—ovarian cancer	3.23e-05	0.00355	CbGpPWpGaD
Zoledronate—CA2—Metabolism—BRIP1—ovarian cancer	3.23e-05	0.00355	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.19e-05	0.00351	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.18e-05	0.0035	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PIK3CG—ovarian cancer	3.03e-05	0.00334	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—YAP1—ovarian cancer	2.94e-05	0.00323	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.9e-05	0.0032	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CHMP4C—ovarian cancer	2.89e-05	0.00319	CbGpPWpGaD
Zoledronate—CA12—Metabolism—YAP1—ovarian cancer	2.83e-05	0.00312	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—NME2—ovarian cancer	2.77e-05	0.00305	CbGpPWpGaD
Zoledronate—CA14—Metabolism—FASN—ovarian cancer	2.74e-05	0.00302	CbGpPWpGaD
Zoledronate—CA14—Metabolism—SLC5A5—ovarian cancer	2.69e-05	0.00297	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	2.69e-05	0.00296	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PIK3CD—ovarian cancer	2.66e-05	0.00293	CbGpPWpGaD
Zoledronate—CA14—Metabolism—SLC2A1—ovarian cancer	2.6e-05	0.00286	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.55e-05	0.00281	CbGpPWpGaD
Zoledronate—ABCC1—Disease—BCL9—ovarian cancer	2.51e-05	0.00276	CbGpPWpGaD
Zoledronate—CA14—Metabolism—CYP1B1—ovarian cancer	2.49e-05	0.00275	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—FASN—ovarian cancer	2.39e-05	0.00264	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—SLC5A5—ovarian cancer	2.35e-05	0.00259	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.35e-05	0.00259	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PIK3CB—ovarian cancer	2.32e-05	0.00256	CbGpPWpGaD
Zoledronate—CA12—Metabolism—FASN—ovarian cancer	2.31e-05	0.00254	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—SLC2A1—ovarian cancer	2.27e-05	0.0025	CbGpPWpGaD
Zoledronate—CA12—Metabolism—SLC5A5—ovarian cancer	2.27e-05	0.0025	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.23e-05	0.00245	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PPP2R1A—ovarian cancer	2.21e-05	0.00244	CbGpPWpGaD
Zoledronate—CA12—Metabolism—SLC2A1—ovarian cancer	2.19e-05	0.00241	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CYP1B1—ovarian cancer	2.18e-05	0.0024	CbGpPWpGaD
Zoledronate—CA2—Metabolism—YAP1—ovarian cancer	2.16e-05	0.00238	CbGpPWpGaD
Zoledronate—CA12—Metabolism—CYP1B1—ovarian cancer	2.1e-05	0.00231	CbGpPWpGaD
Zoledronate—CA14—Metabolism—ABCB1—ovarian cancer	2.05e-05	0.00226	CbGpPWpGaD
Zoledronate—CA14—Metabolism—TYMS—ovarian cancer	2.02e-05	0.00222	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PTEN—ovarian cancer	2.01e-05	0.00221	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PPP2R1A—ovarian cancer	1.93e-05	0.00213	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.92e-05	0.00212	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.92e-05	0.00211	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PPP1CC—ovarian cancer	1.86e-05	0.00205	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PPP2R1A—ovarian cancer	1.86e-05	0.00205	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—ABCB1—ovarian cancer	1.79e-05	0.00198	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	1.79e-05	0.00198	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CYTB—ovarian cancer	1.79e-05	0.00197	CbGpPWpGaD
Zoledronate—CA2—Metabolism—FASN—ovarian cancer	1.76e-05	0.00194	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—TYMS—ovarian cancer	1.76e-05	0.00194	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.75e-05	0.00192	CbGpPWpGaD
Zoledronate—CA2—Metabolism—SLC5A5—ovarian cancer	1.74e-05	0.00191	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	1.73e-05	0.00191	CbGpPWpGaD
Zoledronate—CA12—Metabolism—ABCB1—ovarian cancer	1.73e-05	0.00191	CbGpPWpGaD
Zoledronate—CA12—Metabolism—TYMS—ovarian cancer	1.7e-05	0.00187	CbGpPWpGaD
Zoledronate—CA2—Metabolism—SLC2A1—ovarian cancer	1.68e-05	0.00185	CbGpPWpGaD
Zoledronate—CA14—Metabolism—CAV1—ovarian cancer	1.62e-05	0.00179	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CYP1B1—ovarian cancer	1.61e-05	0.00177	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PPP1CC—ovarian cancer	1.56e-05	0.00172	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—BRIP1—ovarian cancer	1.56e-05	0.00172	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PIK3CG—ovarian cancer	1.48e-05	0.00163	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PPP2R1A—ovarian cancer	1.42e-05	0.00157	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CAV1—ovarian cancer	1.42e-05	0.00156	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PIK3CA—ovarian cancer	1.42e-05	0.00156	CbGpPWpGaD
Zoledronate—ABCC1—Disease—HDAC6—ovarian cancer	1.41e-05	0.00156	CbGpPWpGaD
Zoledronate—CA12—Metabolism—CAV1—ovarian cancer	1.37e-05	0.00151	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	1.37e-05	0.00151	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.36e-05	0.00149	CbGpPWpGaD
Zoledronate—CA2—Metabolism—ABCB1—ovarian cancer	1.32e-05	0.00146	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PIK3CD—ovarian cancer	1.3e-05	0.00143	CbGpPWpGaD
Zoledronate—CA2—Metabolism—TYMS—ovarian cancer	1.3e-05	0.00143	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PIK3CG—ovarian cancer	1.29e-05	0.00143	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PIK3CG—ovarian cancer	1.25e-05	0.00137	CbGpPWpGaD
Zoledronate—ABCC1—Disease—XIAP—ovarian cancer	1.23e-05	0.00135	CbGpPWpGaD
Zoledronate—ABCC1—Disease—SMARCA4—ovarian cancer	1.19e-05	0.00132	CbGpPWpGaD
Zoledronate—ABCC1—Disease—EREG—ovarian cancer	1.17e-05	0.00128	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—AKT1—ovarian cancer	1.16e-05	0.00127	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.14e-05	0.00125	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PIK3CD—ovarian cancer	1.14e-05	0.00125	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PIK3CB—ovarian cancer	1.13e-05	0.00125	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PIK3CD—ovarian cancer	1.1e-05	0.00121	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—YAP1—ovarian cancer	1.05e-05	0.00115	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CAV1—ovarian cancer	1.05e-05	0.00115	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.04e-05	0.00114	CbGpPWpGaD
Zoledronate—ABCC1—Disease—FASN—ovarian cancer	1.02e-05	0.00112	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PARP1—ovarian cancer	1.02e-05	0.00112	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PIK3CB—ovarian cancer	9.91e-06	0.00109	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PTEN—ovarian cancer	9.8e-06	0.00108	CbGpPWpGaD
Zoledronate—ABCC1—Disease—SLC2A1—ovarian cancer	9.69e-06	0.00107	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PIK3CB—ovarian cancer	9.56e-06	0.00105	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PIK3CG—ovarian cancer	9.54e-06	0.00105	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.11e-06	0.001	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PTEN—ovarian cancer	8.57e-06	0.000944	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—FASN—ovarian cancer	8.54e-06	0.000941	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—SLC5A5—ovarian cancer	8.4e-06	0.000925	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PIK3CD—ovarian cancer	8.38e-06	0.000924	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PTEN—ovarian cancer	8.26e-06	0.00091	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PPP2R1A—ovarian cancer	8.24e-06	0.000907	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—SLC2A1—ovarian cancer	8.11e-06	0.000894	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	7.94e-06	0.000875	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CYP1B1—ovarian cancer	7.78e-06	0.000857	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PIK3CB—ovarian cancer	7.31e-06	0.000805	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PIK3CA—ovarian cancer	6.91e-06	0.000762	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PPP2R1A—ovarian cancer	6.9e-06	0.00076	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.86e-06	0.000756	CbGpPWpGaD
Zoledronate—ABCC1—Disease—TERT—ovarian cancer	6.54e-06	0.000721	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—ABCB1—ovarian cancer	6.4e-06	0.000706	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PTEN—ovarian cancer	6.32e-06	0.000696	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—TYMS—ovarian cancer	6.29e-06	0.000693	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CAV1—ovarian cancer	6.05e-06	0.000667	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PIK3CA—ovarian cancer	6.04e-06	0.000666	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PIK3CA—ovarian cancer	5.83e-06	0.000642	CbGpPWpGaD
Zoledronate—ABCC1—Disease—IL6ST—ovarian cancer	5.74e-06	0.000632	CbGpPWpGaD
Zoledronate—CA14—Metabolism—AKT1—ovarian cancer	5.65e-06	0.000622	CbGpPWpGaD
Zoledronate—ABCC1—Disease—APC—ovarian cancer	5.51e-06	0.000607	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CAV1—ovarian cancer	5.07e-06	0.000558	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—AKT1—ovarian cancer	4.94e-06	0.000544	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PIK3CD—ovarian cancer	4.85e-06	0.000534	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.84e-06	0.000533	CbGpPWpGaD
Zoledronate—CA12—Metabolism—AKT1—ovarian cancer	4.76e-06	0.000524	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PIK3CG—ovarian cancer	4.62e-06	0.000509	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PIK3CA—ovarian cancer	4.46e-06	0.000491	CbGpPWpGaD
Zoledronate—ABCC1—Disease—ERBB2—ovarian cancer	4.28e-06	0.000472	CbGpPWpGaD
Zoledronate—ABCC1—Disease—MTOR—ovarian cancer	4.22e-06	0.000465	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PIK3CB—ovarian cancer	4.22e-06	0.000465	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PIK3CD—ovarian cancer	4.06e-06	0.000447	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CDKN1B—ovarian cancer	3.96e-06	0.000437	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CTNNB1—ovarian cancer	3.75e-06	0.000413	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PTEN—ovarian cancer	3.65e-06	0.000402	CbGpPWpGaD
Zoledronate—CA2—Metabolism—AKT1—ovarian cancer	3.64e-06	0.000401	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PIK3CB—ovarian cancer	3.54e-06	0.00039	CbGpPWpGaD
Zoledronate—ABCC1—Disease—STAT3—ovarian cancer	3.26e-06	0.00036	CbGpPWpGaD
Zoledronate—ABCC1—Disease—NRAS—ovarian cancer	3.26e-06	0.000359	CbGpPWpGaD
Zoledronate—ABCC1—Disease—MAPK3—ovarian cancer	3.12e-06	0.000344	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PTEN—ovarian cancer	3.06e-06	0.000337	CbGpPWpGaD
Zoledronate—ABCC1—Disease—MYC—ovarian cancer	3.03e-06	0.000334	CbGpPWpGaD
Zoledronate—ABCC1—Disease—MAPK1—ovarian cancer	2.97e-06	0.000327	CbGpPWpGaD
Zoledronate—ABCC1—Disease—EGFR—ovarian cancer	2.97e-06	0.000327	CbGpPWpGaD
Zoledronate—ABCC1—Disease—KRAS—ovarian cancer	2.8e-06	0.000309	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PIK3CA—ovarian cancer	2.58e-06	0.000284	CbGpPWpGaD
Zoledronate—ABCC1—Disease—HRAS—ovarian cancer	2.38e-06	0.000262	CbGpPWpGaD
Zoledronate—ABCC1—Disease—IL6—ovarian cancer	2.28e-06	0.000251	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PIK3CA—ovarian cancer	2.16e-06	0.000238	CbGpPWpGaD
Zoledronate—ABCC1—Disease—AKT1—ovarian cancer	2.1e-06	0.000232	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—AKT1—ovarian cancer	1.76e-06	0.000194	CbGpPWpGaD
